The European and Developing Countries Clinical Trials Partnership is supporting the development of monoclonal antibodies against Ebola and other filoviruses with EUR 3.4 million.

Omissions

• The exact figure of EUR 3.4 million for monoclonal antibody development specifically could not be confirmed verbatim; the official Global Health EDCTP3 announcement (published 2026-07-01, one week before the session) cites a €4 million total emergency funding mechanism for Ebola research covering surveillance, diagnostics and therapeutics, so the €3.4 million likely refers to a sub-component (therapeutics/monoclonal antibodies) of that €4 million package.
• The funding is tied to the ongoing Bundibugyo ebolavirus outbreak and was announced on 1 July 2026, immediately before the session date of 8 July 2026.
• The entity referred to as 'EDCTP' is now formally the Global Health EDCTP3 Joint Undertaking, the successor to the EDCTP programme.
• Only one primary source was located before the search limit was reached; no independent secondary corroboration of the exact €3.4 million figure was found.

Sources

• PrimaryGlobal Health EDCTP3 (European Commission — EU/EDCTP Joint Undertaking)Global Health EDCTP3 is activating a €4 million emergency funding mechanism to support research activities addressing the ongoing Bundibugyo [ebolavirus outbreak], covering Ebola surveillance, diagnostics and therapeutics.